[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 63 of about 63
58. Sellick GS, Lubbe SJ, Matutes E, Catovsky D, Houlston RS: Microsatellite instability indicative of defects in the major mismatch repair genes is rare in patients with B-cell chronic lymphocytic leukemia: Evaluation with disease stage and family history. Leuk Lymphoma; 2007 Jul;48(7):1320-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability indicative of defects in the major mismatch repair genes is rare in patients with B-cell chronic lymphocytic leukemia: Evaluation with disease stage and family history.
  • A possible role for DNA mismatch repair defects and microsatellite instability (MSI) in the pathogenesis of a number of B-cell lymphoproliferative disorders has recently been debated.
  • To gain further insight into the impact of MSI on B-CLL, we evaluated samples from a series of 982 patients using the mono-satellite markers BAT25 and BAT26, which are highly sensitive in demonstrating classical mismatch repair (MMR) deficiency.
  • Only 1% of cases displayed MSI and this was not correlated with stage of disease or family history of B-CLL.
  • A sub-polymorphic germline variant of BAT25 was identified in one familial case, which was also detected in the patient's affected brother.
  • In conclusion, our study demonstrates that MSI does not have a prominent role in the pathogenesis of B-CLL.
  • [MeSH-major] DNA Mismatch Repair. DNA Repair / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Microsatellite Instability

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613760.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAT26 microsatellite DNA; 0 / Biomarkers, Tumor; 0 / Genetic Markers
  •  go-up   go-down


59. Camacho E, Beà S, Salaverría I, López-Guillermo A, Puig X, Benavente Y, de Sanjosé S, Campo E, Hernández L: Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma. Int J Cancer; 2006 Jan 15;118(2):357-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma.
  • Aurora-A and hMPS1 are kinases involved in spindle checkpoint and centrosome duplication regulation and whose alterations have been associated with cell transformation and chromosome instability in different tumor models.
  • In this study, we have examined the possible alterations of these genes in 58 mantle cell lymphomas (MCLs) and 4 MCL-related cell lines.
  • Aurora-A was also examined in 46 diffuse large B-cell lymphomas (DLBCLs).
  • No Aurora-A gene amplifications were detected in any tumor or cell line, whereas hemizygous hMPS1 gene deletions were observed in 23% of MCLs and 3 of the 4 cell lines.
  • The Aurora-A proposed cancer susceptibility polymorphic variant (P31I) was observed with a similar frequency in MCL, DLBCL, chronic lymphocytic leukemia and in the 431 healthy controls.
  • However, the 3 MCLs and 4 DLBCLs with the homozygous variant of this polymorphism had particular clinical characteristics with an unusual early-age presentation and second epithelial malignancies in MCL and extranodal origin in DLBCL.
  • Although the Aurora-A P31I polymorphic variant is not directly involved in a genetic predisposition to these lymphomas, it may modulate the clinical presentation of these tumors.
  • [MeSH-major] Cell Cycle Proteins / genetics. Genetic Predisposition to Disease. Lymphoma, Mantle-Cell / genetics. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Aurora Kinases. Case-Control Studies. DNA Mutational Analysis. Gene Expression Profiling. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Polymorphism, Genetic. Prognosis. Protein-Tyrosine Kinases. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16080195.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.12.1 / TTK protein, human
  •  go-up   go-down


60. Bentley G, Palutke M, Mohamed AN: Variant t(14;18) in malignant lymphoma: a report of seven cases. Cancer Genet Cytogenet; 2005 Feb;157(1):12-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variant t(14;18) in malignant lymphoma: a report of seven cases.
  • Variant translocations leading to juxtaposing of the BCL2 with either the IGK or IGL gene have been recognized in B-cell malignant lymphoma, although they are rare.
  • We identified seven lymphoma cases that had variant translocations.
  • Morphologically, the lymphomas were categorized as B-cell follicular lymphoma in six cases and in the seventh case as diffuse large cell lymphoma (Richter syndrome) transformed from preexisting chronic lymphocytic leukemia (CLL).
  • In case 2, the variant t(18;22) was seen as a secondary aberration evolving from a trisomy 12 clone.
  • The findings revealed that BCL2 rearrangements in some malignant lymphomas occur through variant simple or complex chromosomal translocations, but always involving the IGH, IGK, or IGL chromosomal site.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15676141.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Ruoppolo M, Pezzica E, Milesi R, Corti D, Mercurio P, Fragapane G: [Neuroendocrine small-cell bladder cancer: our experience]. Urologia; 2010 Oct-Dec;77 Suppl 17:64-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine small-cell bladder cancer: our experience].
  • The small-cell carcinoma represents the most frequent histologic variant described.
  • Small-cell carcinoma is an epithelial tumor associated with a more aggressive behavior and poorer prognosis than transitional cell bladder carcinoma.
  • PATIENTS AND METHODS: We report three cases of pure neuroendocrine small-cell bladder cancer.
  • CONCLUSIONS: In the absence of a prospective study, and because of the rarity of the disease, the best treatment for small-cell bladder cancer remains uncertain.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Fatal Outcome. Gastrointestinal Hemorrhage / etiology. Hematuria / etiology. Humans. Intestinal Neoplasms / complications. Intestinal Neoplasms / secondary. Leukemia, Lymphocytic, Chronic, B-Cell. Liver Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasms, Second Primary. Peritoneal Neoplasms / secondary. Prostatic Neoplasms. Stomach Neoplasms. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308678.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


62. Medeiros LJ, Estrov Z, Rassidakis GZ: Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma. Leuk Res; 2006 Apr;30(4):497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma.
  • The Z-138 cell line, reported in the journal in 1998, was derived from a patient who developed a leukemia initially classified as chronic lymphocytic leukemia in 1987.
  • Splenectomy for massive involvement was required in 1998 and the neoplasm subsequently transformed to an aggressive, mature B-cell leukemia 2 years later.
  • According to the criteria of the current World Health Organization lymphoma classification, this neoplasm is best classified as mantle cell lymphoma, with blastoid transformation present in the terminal phase of disease.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Aged. Cell Line, Tumor. Humans. Immunohistochemistry. Male


63. Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM: MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res; 2010 Aug 1;70(15):6233-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We screened patients with chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), colorectal cancer, endometrial cancer, thyroid cancer, or melanoma, as well as individuals without cancer, and found these variants at low frequencies in most cohorts, including normal individuals.
  • No evidence of increased phosphorylation or transformative capacity by either sequence variant was found.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1479-88 [15735036.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1719-22 [9563489.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):172-87 [16014887.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):352-61 [16397249.001]
  • [Cites] Blood. 2006 Jan 15;107(2):760-8 [16189274.001]
  • [Cites] Cancer Lett. 2006 Aug 8;239(2):227-33 [16171945.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Lancet. 2007 Jan 6;369(9555):29-36 [17208639.001]
  • [Cites] Blood. 2008 May 1;111(9):4788-96 [18252861.001]
  • [Cites] Nat Rev Drug Discov. 2008 Jun;7(6):504-16 [18511928.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1966-9 [18754031.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):27-37 [19898424.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14):2343-50 [10327054.001]
  • [Cites] Oncogene. 2000 Oct 12;19(43):4947-53 [11042681.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6272-81 [14559814.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Nature. 1984 Sep 6-11;311(5981):29-33 [6590967.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Sep;84(18):6379-83 [2819873.001]
  • [Cites] Nat Genet. 1997 May;16(1):68-73 [9140397.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11445-50 [9326629.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):544-9 [15767811.001]
  • (PMID = 20670955.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / CCR NIH HHS / RC / CA146107-01; United States / NCI NIH HHS / CA / RC1 CA146107-01; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / 5 P30 CA069533; United States / NCI NIH HHS / CA / RC1 CA146107; United States / NCRR NIH HHS / RR / UL1 RR024140; United States / NCI NIH HHS / CA / 5P50CA069533; United States / NCI NIH HHS / CA / P30 CA069533
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Receptors, Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  • [Other-IDs] NLM/ NIHMS211280; NLM/ PMC2913476
  •  go-up   go-down






Advertisement